(Incorporated in Israel)

We are a Phase 3 biotech developing steroid-free therapies to treat autoimmune and inflammatory eye diseases that can cause blindness. We are based in Israel.

Our leading drug candidates are based on dazdotuftide to treat non-infectious anterior uveitis without using steroids, which can increase the risk of glaucoma. We are developing an eye drop, known as TRS01, and an injectable drug, known as TRS02, to decrease inflammation without risking the side effects of steroids.

Ocular inflammations are a group of diseases affecting the front and back of the eye. Non-infectious anterior and posterior uveitis are the most known ocular inflammatory diseases. However, ocular inflammation is a critical underlying mechanism in the pathology of other inflammatory eye diseases, such as non-evaporative dry eye, diabetic macular edema (DME), and dry age-related macular degeneration (AMD). Hundreds of millions of people in all age groups are suffering from ocular inflammatory diseases worldwide, conditions that pose severe risks of vision loss and blindness.

(Note: Tarsier Pharma disclosed the terms for its small IPO on May 18, 2026, in an F-1/A filing: 5 ,million shares at a price range of $8.00 to $10.00 to raise $45 million. This is an NYSE-American Exchange listing.)